Ventyx nabs a $152M upsized IPO to challenge BMS' Zeposia—and a backer with intimate...

[cafead]

via Ventyx Biosciences is in the fast lane: Less than a year ago, the biotech emerged from stealth with big plans to dampen down some blockbuster autoimmune/inflammation targets. Then last month, it sprinted to Wall Street with the now standard $100 million IPO ticket.

article source